MYC |
MCF7 (Invasive ductal breast carcinoma) |
45 min with 100 nM Estradiol (Crawford) |
Permissive
Robust
|
Homo sapiens |
ENCSR000DMP
|
MA0147.3
|
MYC |
MCF10A (breast epithelial cells) |
4 hours with 1 uM 4-hydroxytamoxifen dissolved in ethanol (Struhl) |
Permissive
Robust
|
Homo sapiens |
ENCSR000DOM
|
MA0147.3
|
MYC |
MCF10A (breast epithelial cells) |
36 h with 0.01% Ethanol |
Permissive
Robust
|
Homo sapiens |
ENCSR000DOS
|
MA0147.3
|
MYC |
K562 (myelogenous leukemia) |
Interferon gamma treatment - 30 minutes (Snyder) |
Permissive
Robust
|
Homo sapiens |
ENCSR000EGS
|
MA0147.3
|
MYC |
T-cells |
conconavalin for 4 hours |
Permissive
Robust
|
Mus musculus |
GSE37229
...
|
MA0059.1
...
|
MYC |
B-cells |
LPS and 10058-F4 for 4 hours |
Permissive
|
Mus musculus |
GSE37229
...
|
MA0059.1
...
|
MYC |
B-cells |
LPS for 4 hours |
Permissive
|
Mus musculus |
GSE37229
...
|
MA0059.1
...
|
MYC |
embryonic stem cells |
jmjd2b KD |
Permissive
|
Mus musculus |
GSE43229
...
|
MA0059.1
...
|
MYC |
embryonic stem cells |
jmjd2c KD |
Permissive
|
Mus musculus |
GSE43229
...
|
MA0059.1
...
|
MYC |
intestinal crypt cells |
RbKO |
Permissive
Robust
|
Mus musculus |
GSE56008
...
|
MA0059.1
...
|
MYC |
intestinal villus |
RbKO |
Permissive
|
Mus musculus |
GSE56008
...
|
MA0059.1
...
|
MYC |
liver |
tet-Myc (tet-Myc expression off) |
Permissive
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver |
LAPtTA |
Permissive
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver tumor |
tet-Myc/LAPtTA (tet-Myc expression on) |
Permissive
Robust
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver tumor |
tet-Myc/LAPtTA (tet-Myc expression on) |
Permissive
Robust
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver tumor |
tet-Myc/LAPtTA (tet-Myc expression on) |
Permissive
Robust
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver tumor |
tet-Myc/LAPtTA (tet-Myc expression on) |
Permissive
Robust
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver tumor |
tet-Myc/LAPtTA (tet-Myc expression on) |
Permissive
Robust
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver tumor |
tet-Myc/LAPtTA (tet-Myc expression on) |
Permissive
Robust
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver tumor |
tet-Myc/LAPtTA (tet-Myc expression off) |
Permissive
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver tumor |
tet-Myc/LAPtTA (tet-Myc expression off) |
Permissive
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver tumor |
tet-Myc/LAPtTA (tet-Myc expression off) |
Permissive
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
Raji (Burkitt lymphoma) |
100 nM of JQ1 |
Permissive
Robust
|
Homo sapiens |
GSE76191
...
|
MA0059.1
...
|
MYC |
U2OS (osteosarcoma) |
HA-OmoMYCwt, Doxycycline |
Permissive
Robust
|
Homo sapiens |
GSE77328
...
|
MA0059.1
...
|
MYC |
U2OS (osteosarcoma) |
empty vector |
Permissive
Robust
|
Homo sapiens |
GSE77328
...
|
MA0059.1
...
|
MYC |
U2OS (osteosarcoma) |
empty vector, Doxycycline |
Permissive
Robust
|
Homo sapiens |
GSE77328
...
|
MA0059.1
...
|
MYC |
U2OS (osteosarcoma) |
HA-OmoMYCwt |
Permissive
Robust
|
Homo sapiens |
GSE77328
...
|
MA0059.1
...
|
MYC |
U2OS (osteosarcoma) |
HA-OmoMYCwt, Doxycycline |
Permissive
Robust
|
Homo sapiens |
GSE77328
...
|
MA0059.1
...
|
MYC |
HEK293 (embryonic kidney) |
no exogenious myc expression |
Permissive
|
Homo sapiens |
GSE60897
...
|
MA0059.1
...
|
MYC |
HEK293 (embryonic kidney) |
WT-MYC expression |
Permissive
Robust
|
Homo sapiens |
GSE60897
...
|
MA0059.1
...
|
MYC |
HEK293 (embryonic kidney) |
WBM-MYC expressing |
Permissive
Robust
|
Homo sapiens |
GSE60897
...
|
MA0059.1
...
|
MYC |
LNCaP (prostate carcinoma) |
R1881 |
Permissive
Robust
|
Homo sapiens |
GSE73994
...
|
MA0059.1
...
|
MYC |
LNCaP (prostate carcinoma) |
R1881+Doxycycline |
Permissive
Robust
|
Homo sapiens |
GSE73994
...
|
MA0059.1
...
|
MYC |
thyroid gland |
pioglitazone at a concentration of 200 parts per million in irradiated Purina rodent diet 5001 |
Permissive
|
Mus musculus |
GSE85648
...
|
MA0059.1
...
|
MYC |
U87MG(glioblastoma) |
Untreated with Dox |
Permissive
|
Homo sapiens |
GSE86511
...
|
MA0059.1
...
|
MYC |
U87MG(glioblastoma) |
Dox treated |
Permissive
|
Homo sapiens |
GSE86511
...
|
MA0059.1
...
|
MYC |
BT168 (glioblastoma stem cells) |
Untreated with Dox |
Permissive
Robust
|
Homo sapiens |
GSE86511
...
|
MA0059.1
...
|
MYC |
BT168 (glioblastoma stem cells) |
Dox treated |
Permissive
|
Homo sapiens |
GSE86511
...
|
MA0059.1
...
|
MYC |
HCT-116 (colon carcinoma) |
na |
Permissive
Robust
|
Homo sapiens |
GSE86556
...
|
MA0059.1
...
|
MYC |
bone marrow-derived macrophages |
IL4 (10ng/ml) for 2hrs |
Permissive
Robust
|
Mus musculus |
GSE84518
...
|
MA0059.1
...
|
MYC |
bone marrow-derived macrophages |
IL4 (10ng/ml) for 4hrs |
Permissive
Robust
|
Mus musculus |
GSE84518
...
|
MA0059.1
...
|
MYC |
bone marrow-derived macrophages |
IFNg (100 ng/ml) and IL4 (10ng/ml) for 2hrs |
Permissive
Robust
|
Mus musculus |
GSE84518
...
|
MA0059.1
...
|
MYC |
bone marrow-derived macrophages |
IFNg (100 ng/ml) and IL4 (10ng/ml) for 4hrs |
Permissive
Robust
|
Mus musculus |
GSE84518
...
|
MA0059.1
...
|
MYC |
E??-Myc lymphoma |
DMSO vehicle |
Permissive
Robust
|
Mus musculus |
GSE94130
...
|
MA0059.1
...
|
MYC |
E??-Myc lymphoma |
1000nM JQ1 |
Permissive
Robust
|
Mus musculus |
GSE94130
...
|
MA0059.1
...
|
MYC |
Eph4 (mammary epithelial cells) |
DMSO |
Permissive
Robust
|
Mus musculus |
GSE98002
...
|
MA0059.1
...
|
MYC |
Eph4 (mammary epithelial cells) |
AU-1 (5uM) |
Permissive
Robust
|
Mus musculus |
GSE98002
...
|
MA0059.1
...
|
MYC |
P493-6 (B-cell lymphoma) |
0.2 µg/mL Tetracycline (Myc transgene repressed) |
Permissive
|
Homo sapiens |
GSE51004
...
|
MA0059.1
...
|
MYC |
P493-6 (B-cell lymphoma) |
200 nM OHT (endogenous Myc activated) and 0.2 µg/mL Tetracyclin (Myc transgene repressed) |
Permissive
Robust
|
Homo sapiens |
GSE51004
...
|
MA0059.1
...
|
MYC |
P493-6 (B-cell lymphoma) |
none (Myc transgene expressed) |
Permissive
Robust
|
Homo sapiens |
GSE51004
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
c-mycflox/flox; in vitro infected with MycER; EtOH |
Permissive
Robust
|
Mus musculus |
GSE51004
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
c-mycflox/flox; in vitro infected with MycER; 400 nM 4-hydroxytamoxifen |
Permissive
Robust
|
Mus musculus |
GSE51004
...
|
MA0059.1
...
|
MYC |
P493-6 (B-cell lymphoma) |
0.2 µg/mL Tetracycline (Myc transgene repressed) for 72h and then released in fresh medium without Tetracycline for 1h |
Permissive
Robust
|
Homo sapiens |
GSE51004
...
|
MA0059.1
...
|
MYC |
P493-6 (B-cell lymphoma) |
0.2 µg/mL Tetracycline (Myc transgene repressed) for 72h and then released in fresh medium without Tetracycline for 24h |
Permissive
Robust
|
Homo sapiens |
GSE51004
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
serum starved (0% FBS for 48h), then serum stimulated (10% FBS for 1h) |
Permissive
Robust
|
Mus musculus |
GSE51004
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
serum starved (0% FBS for 48h), then serum stimulated (10% FBS for 2h) |
Permissive
Robust
|
Mus musculus |
GSE51004
...
|
MA0059.1
...
|
MYC |
liver tumor |
LAP-tta-Arid1afl/fl;Alb-cre;TRE-MYC |
Permissive
Robust
|
Mus musculus |
GSE102607
...
|
MA0059.1
...
|
MYC |
liver tumor |
LAP-tta-Arid1afl/+;Alb-cre;TRE-MYC |
Permissive
Robust
|
Mus musculus |
GSE102607
...
|
MA0059.1
...
|
MYC |
liver tumor |
LAP-tta-Arid1aflfl;TRE-MYC (WT) |
Permissive
Robust
|
Mus musculus |
GSE102607
...
|
MA0059.1
...
|
MYC |
NCI-H2171 (small cell lung carcinoma) |
Treatment: Treatment withKL-1 or KL-2 inhibitors was administrated only once; Genotype: mutation by amplification of MYC; |
Permissive
Robust
|
Homo sapiens |
GSE112608
...
|
MA0059.1
...
|
MYC |
HEK293T (embryonic kidney) |
Treatment: withKL-1 or KL-2 inhibitors was administrated only once; Genotype: cells lentiviral infected with control vector; |
Permissive
Robust
|
Homo sapiens |
GSE112608
...
|
MA0059.1
...
|
MYC |
HEK293T (embryonic kidney) |
Treatment: withKL-1 or KL-2 inhibitors was administrated only once; Genotype: cells lentiviral infected shRNA targeting MYC; |
Permissive
Robust
|
Homo sapiens |
GSE112608
...
|
MA0059.1
...
|
MYC |
MCF10A (breast epithelial cells) |
Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR; |
Permissive
Robust
|
Homo sapiens |
GSE100335
...
|
MA0059.1
...
|
MYC |
MCF10A (breast epithelial cells) |
Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR; |
Permissive
Robust
|
Homo sapiens |
GSE100335
...
|
MA0059.1
...
|
MYC |
MCF10A (breast epithelial cells) |
Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR; |
Permissive
Robust
|
Homo sapiens |
GSE100335
...
|
MA0059.1
...
|
MYC |
MCF10A (breast epithelial cells) |
Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1; |
Permissive
Robust
|
Homo sapiens |
GSE100335
...
|
MA0059.1
...
|
MYC |
MCF10A (breast epithelial cells) |
Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1; |
Permissive
Robust
|
Homo sapiens |
GSE100335
...
|
MA0059.1
...
|
MYC |
MCF10A (breast epithelial cells) |
Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1; |
Permissive
Robust
|
Homo sapiens |
GSE100335
...
|
MA0059.1
...
|
MYC |
MCF10A (breast epithelial cells) |
Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4; |
Permissive
Robust
|
Homo sapiens |
GSE100335
...
|
MA0059.1
...
|
MYC |
MCF10A (breast epithelial cells) |
Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4; |
Permissive
Robust
|
Homo sapiens |
GSE100335
...
|
MA0059.1
...
|
MYC |
MCF10A (breast epithelial cells) |
Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4; |
Permissive
Robust
|
Homo sapiens |
GSE100335
...
|
MA0059.1
...
|
MYC |
P493-6 (B-cell lymphoma) |
Genotype: scramble shRNA; |
Permissive
|
Homo sapiens |
GSE101853
...
|
MA0059.1
...
|
MYC |
P493-6 (B-cell lymphoma) |
Genotype: Dpy30 shRNA; |
Permissive
|
Homo sapiens |
GSE101853
...
|
MA0059.1
...
|
MYC |
MRC-5 (fetal lung fibroblasts) |
Genotype: wildtype Passage: 8 |
Permissive
|
Homo sapiens |
GSE81899
...
|
MA0059.1
...
|
MYC |
MRC-5 (fetal lung fibroblasts) |
Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8 |
Permissive
Robust
|
Homo sapiens |
GSE81899
...
|
MA0059.1
...
|
MYC |
MRC-5 (fetal lung fibroblasts) |
Treatment: Oct4, Sox2-VP16 (strong activator), Klf4 and Myc addition for 5 days Passage: 8 |
Permissive
|
Homo sapiens |
GSE81899
...
|
MA0059.1
...
|
MYC |
CUTLL1 (T-cell lymphoblastic lymphoma 1) |
Treatment: no |
Permissive
Robust
|
Homo sapiens |
GSE90716
...
|
MA0059.1
...
|
MYC |
Secondary MEF cells |
Treatment: DOX induction, day1 Genotype: Mbd3f/- cell line |
Permissive
Robust
|
Mus musculus |
GSE102517
...
|
MA0059.1
...
|
MYC |
Secondary MEF cells |
Treatment: DOX induction, day 2 Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0059.1
...
|
MYC |
Secondary MEF cells |
Treatment: DOX induction, N2B27 2i\\LIF medium, day3 Genotype: Mbd3f/- cell line |
Permissive
Robust
|
Mus musculus |
GSE102517
...
|
MA0059.1
...
|
MYC |
Secondary MEF cells |
Treatment: DOX induction, N2B27 2i\\LIF medium, day4 Genotype: Mbd3f/- cell line |
Permissive
Robust
|
Mus musculus |
GSE102517
...
|
MA0059.1
...
|
MYC |
Secondary MEF cells |
Treatment: DOX induction, N2B27 2i\\LIF medium, day5 Genotype: Mbd3f/- cell line |
Permissive
Robust
|
Mus musculus |
GSE102517
...
|
MA0059.1
...
|
MYC |
Secondary MEF cells |
Treatment: DOX induction, N2B27 2i\\LIF medium, day6 Genotype: Mbd3f/- cell line |
Permissive
Robust
|
Mus musculus |
GSE102517
...
|
MA0059.1
...
|
MYC |
Secondary MEF cells |
Treatment: DOX induction, N2B27 2i\\LIF medium, day7 Genotype: Mbd3f/- cell line |
Permissive
Robust
|
Mus musculus |
GSE102517
...
|
MA0059.1
...
|
MYC |
V6.5 (embryonic stem cells) |
Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0059.1
...
|
MYC |
induced pluripotent stem cells |
Genotype: Mbd3f/- cell line |
Permissive
Robust
|
Mus musculus |
GSE102517
...
|
MA0059.1
...
|
MYC |
MEF-1 (mouse embryonic fibroblasts) |
Genotype: Mbd3f/- cell line |
Permissive
Robust
|
Mus musculus |
GSE102517
...
|
MA0059.1
...
|
MYC |
pancreas |
Genotype: Ela1-myc mice Age: 8 weeks-old |
Permissive
Robust
|
Mus musculus |
GSE77409
...
|
MA0059.1
...
|
MYC |
liver |
Genotype: R26-rtTA (wildtype) |
Permissive
|
Mus musculus |
GSE83863
...
|
MA0059.1
...
|
MYC |
liver |
Genotype: R26-rtTA, tet-YAP |
Permissive
|
Mus musculus |
GSE83863
...
|
MA0059.1
...
|
MYC |
liver |
Genotype: R26-rtTA, tet-YAP, tet-Myc |
Permissive
|
Mus musculus |
GSE83863
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
Treatment: 400nM 4-hydroxytamoxifen Cell type: immortalized embryonic fibroblasts Genotype: 3T9MycER |
Permissive
Robust
|
Mus musculus |
GSE83866
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
Time: 0 min Treatment: infected with MycER, MycER activation was achieved by addition of 400nM of the synthetic 4-hydroxytamoxifen (OHT; Sigma-Aldrich) Genotype: c-myc flox/flox (c-myc knockout) Source: embryonic fibroblasts, E13.5 |
Permissive
Robust
|
Mus musculus |
GSE98419
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
Time: 10 min Treatment: infected with MycER, MycER activation was achieved by addition of 400nM of the synthetic 4-hydroxytamoxifen (OHT; Sigma-Aldrich) Genotype: c-myc flox/flox (c-myc knockout) Source: embryonic fibroblasts, E13.5 |
Permissive
Robust
|
Mus musculus |
GSE98419
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
Time: 20 min Treatment: infected with MycER, MycER activation was achieved by addition of 400nM of the synthetic 4-hydroxytamoxifen (OHT; Sigma-Aldrich) Genotype: c-myc flox/flox (c-myc knockout) Source: embryonic fibroblasts, E13.5 |
Permissive
Robust
|
Mus musculus |
GSE98419
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
Time: 30 min Treatment: infected with MycER, MycER activation was achieved by addition of 400nM of the synthetic 4-hydroxytamoxifen (OHT; Sigma-Aldrich) Genotype: c-myc flox/flox (c-myc knockout) Source: embryonic fibroblasts, E13.5 |
Permissive
Robust
|
Mus musculus |
GSE98419
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
Time: 2hrs Treatment: infected with MycER, MycER activation was achieved by addition of 400nM of the synthetic 4-hydroxytamoxifen (OHT; Sigma-Aldrich) Genotype: c-myc flox/flox (c-myc knockout) Source: embryonic fibroblasts, E13.5 |
Permissive
Robust
|
Mus musculus |
GSE98419
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
Time: 4 hrsTreatment: infected with MycER, MycER activation was achieved by addition of 400nM of the synthetic 4-hydroxytamoxifen (OHT; Sigma-Aldrich) Genotype: c-myc flox/flox (c-myc knockout) Source: embryonic fibroblasts, E13.5 |
Permissive
Robust
|
Mus musculus |
GSE98419
...
|
MA0059.1
...
|
MYC |
Tet21N (neuroblastoma) |
Treatment: 1ug/mL doxycycline for 7 days prior to harvest Genotype: wildtype MYC Passage: 10 -15 Cell type: neuroblastoma cell line |
Permissive
Robust
|
Homo sapiens |
GSE117406
...
|
MA0059.1
...
|
MYC |
embryonic fibroblasts |
Strain:C57BL/6 Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE109458
...
|
MA0059.1
...
|
MYC |
embryonic fibroblasts |
Strain:C57BL/6 Genotype: PIN1 knockout |
Permissive
Robust
|
Mus musculus |
GSE109458
...
|
MA0059.1
...
|
MYC |
G401 (rhabdoid tumor of the kidney) |
Passage: ten-thirty; Genotype: EGFP transfection; |
Permissive
Robust
|
Homo sapiens |
GSE109310
...
|
MA0059.1
...
|
MYC |
G401 (rhabdoid tumor of the kidney) |
Passage: ten-thirty; Genotype: EGFP transfection; |
Permissive
Robust
|
Homo sapiens |
GSE109310
...
|
MA0059.1
...
|
MYC |
G401 (rhabdoid tumor of the kidney) |
Passage: ten-thirty; Genotype: SNF5 transfection; |
Permissive
Robust
|
Homo sapiens |
GSE109310
...
|
MA0059.1
...
|
MYC |
G401 (rhabdoid tumor of the kidney) |
Passage: ten-thirty; Genotype: SNF5 transfection; |
Permissive
|
Homo sapiens |
GSE109310
...
|
MA0059.1
...
|
MYC |
MM1.S (plasma cell myeloma) |
DMSO |
Permissive
Robust
|
Homo sapiens |
GSE36354
|
MA0147.3
|
MYC |
BJ (fibroblasts) |
INDUCED |
Permissive
Robust
|
Homo sapiens |
GSE36570
|
MA0147.3
|
MYC |
MM1.S (plasma cell myeloma) |
JQ1 |
Permissive
Robust
|
Homo sapiens |
GSE42161
|
MA0147.3
|
MYC |
MDA-MB-453 (breast adenocarcinoma) |
DHT |
Permissive
|
Homo sapiens |
GSE45201
|
MA0147.3
|
MYC |
|
primary |
Permissive
Robust
|
Homo sapiens |
GSE66252
|
MA0147.3
|
MYC |
GM12878 (female B-cells lymphoblastoid cell line) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000DKU
|
MA0147.3
|
MYC |
WA01 (H1, human embryonic stem cells) |
|
Permissive
|
Homo sapiens |
ENCSR000DLI
|
MA0147.3
|
MYC |
HeLa S3 (cervical adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000DLN
|
MA0147.3
|
MYC |
HepG2 (hepatoblastoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000DLR
|
MA0147.3
|
MYC |
HUVEC-C (HUVEC, umbilical vein endothelial cells) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000DLU
|
MA0147.3
|
MYC |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
|
Homo sapiens |
ENCSR000DMJ
|
MA0147.3
|
MYC |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
|
Homo sapiens |
ENCSR000DMM
|
MA0147.3
|
MYC |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000DMQ
|
MA0147.3
|
MYC |
A549 (lung carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000DYC
|
MA0147.3
|
MYC |
WA01 (H1, human embryonic stem cells) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000EBY
|
MA0147.3
|
MYC |
K562 (myelogenous leukemia) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000EGJ
|
MA0147.3
|
MYC |
NB4 (acute promyelocytic leukemia ) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000EHR
|
MA0147.3
|
MYC |
K562 (myelogenous leukemia) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000FAG
|
MA0147.3
|
MYC |
K562 (myelogenous leukemia) |
|
Permissive
Robust
|
Homo sapiens |
GSE19547
...
|
MA0059.1
...
|
MYC |
GM12878 (female B-cells lymphoblastoid cell line) |
|
Permissive
Robust
|
Homo sapiens |
GSE30399
...
|
MA0059.1
...
|
MYC |
embryonic stem cells |
|
Permissive
Robust
|
Mus musculus |
GSE11431
...
|
MA0059.1
...
|
MYC |
WA01 (H1, human embryonic stem cells) |
|
Permissive
|
Homo sapiens |
GSE30226
...
|
MA0059.1
...
|
MYC |
HUVEC-C (HUVEC, umbilical vein endothelial cells) |
|
Permissive
Robust
|
Homo sapiens |
GSE30226
...
|
MA0059.1
...
|
MYC |
normal epidermal keratinocytes |
|
Permissive
Robust
|
Homo sapiens |
GSE30226
...
|
MA0059.1
...
|
MYC |
GM12878 (female B-cells lymphoblastoid cell line) |
|
Permissive
Robust
|
Homo sapiens |
GSE30226
...
|
MA0059.1
...
|
MYC |
HeLa S3 (cervical adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE30226
...
|
MA0059.1
...
|
MYC |
HepG2 (hepatoblastoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE30226
...
|
MA0059.1
...
|
MYC |
K562 (myelogenous leukemia) |
|
Permissive
Robust
|
Homo sapiens |
GSE30226
...
|
MA0059.1
...
|
MYC |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE32692
...
|
MA0059.1
...
|
MYC |
FB8470 (fibroblasts) |
|
Permissive
Robust
|
Homo sapiens |
GSE32692
...
|
MA0059.1
...
|
MYC |
FB0167P (progeria fibroblasts) |
|
Permissive
|
Homo sapiens |
GSE32692
...
|
MA0059.1
...
|
MYC |
D54 (H54, Human glioblastoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE32692
...
|
MA0059.1
...
|
MYC |
MEL cell line |
|
Permissive
Robust
|
Mus musculus |
ENCSR000EUA
...
|
MA0059.1
...
|
MYC |
CH12.LX (Mouse lymphoma) |
|
Permissive
Robust
|
Mus musculus |
ENCSR000ERN
...
|
MA0059.1
...
|
MYC |
pro-B cells |
|
Permissive
Robust
|
Mus musculus |
GSE40173
...
|
MA0059.1
...
|
MYC |
HeLa (cervical adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE43227
...
|
MA0059.1
...
|
MYC |
embryonic stem cells |
|
Permissive
|
Mus musculus |
GSE43229
...
|
MA0059.1
...
|
MYC |
embryonic stem cells |
|
Permissive
Robust
|
Mus musculus |
GSE48175
...
|
MA0059.1
...
|
MYC |
CD8+ T-cells |
|
Permissive
Robust
|
Mus musculus |
GSE58075
...
|
MA0059.1
...
|
MYC |
J1 (embryonic stem cells) |
|
Permissive
Robust
|
Mus musculus |
GSE48666
...
|
MA0059.1
...
|
MYC |
intestinal crypt cells |
|
Permissive
Robust
|
Mus musculus |
GSE56008
...
|
MA0059.1
...
|
MYC |
intestinal villus |
|
Permissive
Robust
|
Mus musculus |
GSE56008
...
|
MA0059.1
...
|
MYC |
multipotent otic progenitors |
|
Permissive
Robust
|
Mus musculus |
GSE62513
...
|
MA0059.1
...
|
MYC |
medulloblastoma, type G3 |
|
Permissive
Robust
|
Mus musculus |
GSE64425
...
|
MA0059.1
...
|
MYC |
liver |
|
Permissive
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
liver |
|
Permissive
|
Mus musculus |
GSE76042
...
|
MA0059.1
...
|
MYC |
Raji (Burkitt lymphoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE76191
...
|
MA0059.1
...
|
MYC |
HCT-116 (colon carcinoma) |
|
Permissive
|
Homo sapiens |
GSE78064
...
|
MA0059.1
...
|
MYC |
HCT-116 (colon carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE78064
...
|
MA0059.1
...
|
MYC |
HCT-116 (colon carcinoma) |
|
Permissive
|
Homo sapiens |
GSE78064
...
|
MA0059.1
...
|
MYC |
HCT-116 (colon carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE78064
...
|
MA0059.1
...
|
MYC |
HCT-116 (colon carcinoma) |
|
Permissive
|
Homo sapiens |
GSE78064
...
|
MA0059.1
...
|
MYC |
HCT-116 (colon carcinoma) |
|
Permissive
|
Homo sapiens |
GSE78064
...
|
MA0059.1
...
|
MYC |
B-cells |
|
Permissive
Robust
|
Mus musculus |
GSE80669
...
|
MA0059.1
...
|
MYC |
HUES64 (embryonic stem cells) |
|
Permissive
Robust
|
Homo sapiens |
GSE61475
...
|
MA0059.1
...
|
MYC |
HUES64 (embryonic stem cells) |
|
Permissive
Robust
|
Homo sapiens |
GSE61475
...
|
MA0059.1
...
|
MYC |
HUES64 (embryonic stem cells) |
|
Permissive
Robust
|
Homo sapiens |
GSE61475
...
|
MA0059.1
...
|
MYC |
HUES64 (embryonic stem cells) |
|
Permissive
Robust
|
Homo sapiens |
GSE61475
...
|
MA0059.1
...
|
MYC |
HUES64 (embryonic stem cells) |
|
Permissive
Robust
|
Homo sapiens |
GSE61475
...
|
MA0059.1
...
|
MYC |
GEN2.2 (blastic plasmacytoid dendritic cell neoplasm) |
|
Permissive
Robust
|
Homo sapiens |
GSE70275
...
|
MA0059.1
...
|
MYC |
MDA-MB-468 (breast adenocarcinoma) |
|
Permissive
|
Homo sapiens |
GSE81381
...
|
MA0059.1
...
|
MYC |
blastocyst B-cells |
|
Permissive
|
Mus musculus |
GSE82144
...
|
MA0059.1
...
|
MYC |
HT1080 (fibrosarcoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE86504
...
|
MA0059.1
...
|
MYC |
PB115 (lung cancer) |
|
Permissive
Robust
|
Mus musculus |
GSE87034
...
|
MA0059.1
...
|
MYC |
PB119 (lung cancer) |
|
Permissive
Robust
|
Mus musculus |
GSE87034
...
|
MA0059.1
...
|
MYC |
PB120 (lung cancer) |
|
Permissive
Robust
|
Mus musculus |
GSE87034
...
|
MA0059.1
...
|
MYC |
bone marrow-derived macrophages |
|
Permissive
Robust
|
Mus musculus |
GSE84518
...
|
MA0059.1
...
|
MYC |
embryonic fibroblasts |
|
Permissive
Robust
|
Mus musculus |
GSE90893
...
|
MA0059.1
...
|
MYC |
embryonic fibroblasts expressing OSKM for 48h |
|
Permissive
|
Mus musculus |
GSE90893
...
|
MA0059.1
...
|
MYC |
embryonic stem cells |
|
Permissive
Robust
|
Mus musculus |
GSE90893
...
|
MA0059.1
...
|
MYC |
pre-induced pluripotent stem cells |
|
Permissive
Robust
|
Mus musculus |
GSE90893
...
|
MA0059.1
...
|
MYC |
HUVEC-C (HUVEC, umbilical vein endothelial cells) |
|
Permissive
|
Homo sapiens |
GSE93030
...
|
MA0059.1
...
|
MYC |
MDA231-LM2-4175 (breast adenocarcinoma) |
|
Permissive
|
Homo sapiens |
GSE95303
...
|
MA0059.1
...
|
MYC |
spleen B-cells |
|
Permissive
Robust
|
Mus musculus |
GSE51004
...
|
MA0059.1
...
|
MYC |
3T9 fibroblasts |
|
Permissive
Robust
|
Mus musculus |
GSE51004
...
|
MA0059.1
...
|
MYC |
spleen B-cells |
|
Permissive
Robust
|
Mus musculus |
GSE51004
...
|
MA0059.1
...
|
MYC |
B-cells, lymphnode-derived |
|
Permissive
Robust
|
Mus musculus |
GSE51004
...
|
MA0059.1
...
|
MYC |
LCL (lymphoblastoid cell line) |
|
Permissive
|
Homo sapiens |
ERP004110
|
MA0147.3
|
MYC |
BL41(Burkitt lymphoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE30726
|
MA0147.3
|
MYC |
Blue1 (sporadic Burkitt lymphoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE30726
|
MA0147.3
|
MYC |
CA-46 (Burkitt lymphoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE30726
|
MA0147.3
|
MYC |
|
|
Permissive
Robust
|
Homo sapiens |
GSE30726
|
MA0147.3
|
MYC |
Raji (Burkitt lymphoma) |
|
Permissive
|
Homo sapiens |
GSE30726
|
MA0147.3
|
MYC |
|
|
Permissive
|
Homo sapiens |
GSE34419
|
MA0147.3
|
MYC |
NCI-H2171 (small cell lung carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE36354
|
MA0147.3
|
MYC |
|
|
Permissive
Robust
|
Homo sapiens |
GSE36354
|
MA0147.3
|
MYC |
NCI-H128 (small cell lung carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE41105
|
MA0147.3
|
MYC |
NCI-H2171 (small cell lung carcinoma) |
|
Permissive
|
Homo sapiens |
GSE41105
|
MA0147.3
|
MYC |
P493-6 (B-cell lymphoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE42262
|
MA0147.3
|
MYC |
HeLa (cervical adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE44672
|
MA0147.3
|
MYC |
|
|
Permissive
|
Homo sapiens |
GSE47152
|
MA0147.3
|
MYC |
MDA-MB-231 (breast adenocarcinoma) |
|
Permissive
|
Homo sapiens |
GSE48602
|
MA0147.3
|
MYC |
|
|
Permissive
Robust
|
Homo sapiens |
GSE70001
|
MA0147.3
|
MYC |
Jurkat (T-cells) |
|
Permissive
|
Homo sapiens |
GSE83777
|
MA0147.3
|
MYC |
CD34+ cells |
|
Permissive
Robust
|
Homo sapiens |
GSE85488
|
MA0147.3
|
MYC |
P493-6 (B-cell lymphoma) |
CMYC_1H |
Permissive
Robust
|
Homo sapiens |
GSE36354
|
MA0147.3
|
MYC |
P493-6 (B-cell lymphoma) |
CMYC_24H |
Permissive
Robust
|
Homo sapiens |
GSE36354
|
MA0147.3
|
MYC |
U2OS (osteosarcoma) |
Doxy |
Permissive
Robust
|
Homo sapiens |
GSE44672
|
MA0147.3
|
MYC |
GP5d (colon adenocarcinoma) |
SIRAD21 |
Permissive
|
Homo sapiens |
GSE51234
|
MA0147.3
|
MYC |
LoVo (colorectal adenocarcinoma) |
PHASEM |
Permissive
|
Homo sapiens |
GSE51290
|
MA0147.3
|
MYC |
LoVo (colorectal adenocarcinoma) |
PHASES |
Permissive
|
Homo sapiens |
GSE51290
|
MA0147.3
|
MYC |
LS174T (colon adenocarcinoma) |
BI8622 |
Permissive
Robust
|
Homo sapiens |
GSE59223
|
MA0147.3
|
MYC |
LS174T (colon adenocarcinoma) |
DMSO |
Permissive
Robust
|
Homo sapiens |
GSE59223
|
MA0147.3
|
MYC |
P493-6 (B-cell lymphoma) |
SHCTR |
Permissive
Robust
|
Homo sapiens |
GSE60223
|
MA0147.3
|
MYC |
P493-6 (B-cell lymphoma) |
SHTERC |
Permissive
Robust
|
Homo sapiens |
GSE60223
|
MA0147.3
|
MYC |
P493-6 (B-cell lymphoma) |
SHTERT |
Permissive
Robust
|
Homo sapiens |
GSE60223
|
MA0147.3
|
MYC |
HFF (foreskin fibroblast) |
OHT |
Permissive
Robust
|
Homo sapiens |
GSE65544
|
MA0147.3
|
MYC |
HFF (foreskin fibroblast) |
OHT_SHBPTF |
Permissive
Robust
|
Homo sapiens |
GSE65544
|
MA0147.3
|
MYC |
BE2C |
SHCTR |
Permissive
|
Homo sapiens |
GSE70098
|
MA0147.3
|
MYC |
BE2C |
SHWDR5 |
Permissive
|
Homo sapiens |
GSE70098
|
MA0147.3
|
MYC |
U2OS (osteosarcoma) |
Doxy |
Permissive
Robust
|
Homo sapiens |
GSE77356
|
MA0147.3
|
MYC |
U2OS (osteosarcoma) |
SHMYC |
Permissive
Robust
|
Homo sapiens |
GSE77356
|
MA0147.3
|
MYC |
U2OS (osteosarcoma) |
SHRCTR |
Permissive
Robust
|
Homo sapiens |
GSE77356
|
MA0147.3
|
MYC |
P493-6 (B-cell lymphoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE36354
|
MA0147.3
|
MYC |
U2OS (osteosarcoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE44672
|
MA0147.3
|
MYC |
GP5d (colon adenocarcinoma) |
|
Permissive
|
Homo sapiens |
GSE51234
|
MA0147.3
|
MYC |
U2OS (osteosarcoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE77356
|
MA0147.3
|